As Keryx Moves Closer To Phase III Results, Partnership Options Heat Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data readout on perifosine in colorectal cancer patients will spark a partnership or acquisition, CEO Ron Bentsur predicts during a Q2 call.
You may also be interested in...
Keryx Share Price Tumbles Sharply On Phase III Failure Of Perifosine
With disappointing data in advanced colorectal cancer, Keryx is expected to abandon development of the Akt pathway inhibitor and focus all efforts on Phase III candidate Zerenex in ESRD.
So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd
Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.